Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $51.86 and last traded at $51.97, with a volume of 199627 shares trading hands. The stock had previously closed at $50.17.
Wall Street Analyst Weigh In
Several analysts recently weighed in on SUPN shares. Weiss Ratings reissued a "hold (c)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research upgraded Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 17th. Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 30th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, October 3rd. Finally, Piper Sandler raised shares of Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $40.00 to $65.00 in a research note on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $64.00.
Check Out Our Latest Stock Report on SUPN
Supernus Pharmaceuticals Price Performance
The stock has a market cap of $2.89 billion, a price-to-earnings ratio of 44.86 and a beta of 0.78. The firm's fifty day moving average price is $45.90 and its two-hundred day moving average price is $37.32.
Insider Transactions at Supernus Pharmaceuticals
In related news, Director Frederick M. Hudson sold 7,457 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total value of $315,132.82. Following the completion of the sale, the director owned 46,307 shares of the company's stock, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Timothy C. Dec sold 11,780 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $44.49, for a total transaction of $524,092.20. Following the sale, the chief financial officer owned 1,246 shares of the company's stock, valued at $55,434.54. This trade represents a 90.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 362,741 shares of company stock worth $16,390,592 in the last three months. Insiders own 8.80% of the company's stock.
Institutional Investors Weigh In On Supernus Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Rubric Capital Management LP bought a new position in Supernus Pharmaceuticals in the 2nd quarter valued at about $21,908,000. Armistice Capital LLC raised its stake in shares of Supernus Pharmaceuticals by 7.4% in the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock worth $170,169,000 after purchasing an additional 360,000 shares during the last quarter. Sofinnova Investments Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 53.5% in the second quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company's stock valued at $25,192,000 after purchasing an additional 278,575 shares in the last quarter. GW&K Investment Management LLC grew its holdings in Supernus Pharmaceuticals by 14.6% during the first quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock worth $45,275,000 after buying an additional 176,091 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in Supernus Pharmaceuticals in the 1st quarter valued at $4,393,000.
About Supernus Pharmaceuticals
(
Get Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
